Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Egypt / NCT07460869
Active, not recruiting Not applicable

Compare Between the Effect of CGF and PRF on Revascularization of Immature Roots of the Mandibular Permanent First Molar

NCT07460869 · tracked via the Priya Life Science Egypt tracker
Sponsor
Minia University
Phase
Not applicable
Started
2025-01-10
Last updated
2026-03-10

Condition(s) studied

Revascularization of Immature Young Permenant Teeth

Investigational drug(s) / intervention(s)

Revascularization/Conservative management

Revascularization/Conservative management: Compare the effect of CGF and PRF in the revascularization of immature mandibular first permanent molar using bio-dentine

Study summary

in this study investigators do revascularization technique to promote root growth of immature mandibular first permanent molar by using CGF and PRF from blood sample of patients

Eligibility

Sex
ALL
Min age
6 Years
Max age
8 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Children with immature necrotic lower fitrst permanent molar. * No history of repeated pathosis or cellulitis. * Patients accept the treatment modality. * Patient-free from systemic, allergic or genetic problems. Exclusion Criteria: * Tooth mobility. * Teeth with non-restorable crowns. * Children with facial cellulitis * Children with draining fistula * Children with a history of recurrent preapical pathosis

Primary outcome measure(s)

  • root growth — 18 months
    change root length

Trial sites (1)

FacilityCityRegionStatus
Faculty of Dentistry Minya University Minya Minya Governorate

More Minia University trials in Egypt

Prognostic Outcomes of Total Mesopancreas Excision for Pancreatic Head Cancer Recruiting
Reinforced Pancreaticojejunostomy With or Without glubran2 Recruiting
Alpha-Lipoic Acid in Mitigating Cisplatin-Induced Nephrotoxicity Recruiting
Effect of Cyperus Articulatus on Bacterial Reduction and Postoperative Pain Recruiting
Assessing the Role of Proton Pump Inhibitors in Reducing Aspiration Incidence in Pediatric Laryngomalacia Cases Recruiting

Other trials for the same condition

The Present Study Was Conducted to Evaluate Bioceramic Root Repair Material Versus Bio MTA in Revascularization of Immature Young Permenant Teeth. Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07460869 on ClinicalTrials.gov ↗ ← All trials in Egypt